E-ISSN: 3023-6215
The Prognostic Significance of Modified Lymph Node Ratio and LODDS in HER-2(+) Breast Cancer
PDF
Cite
Share
Request
Clinical Research
VOLUME: 31 ISSUE: 2
P: 253 - 260
2021

The Prognostic Significance of Modified Lymph Node Ratio and LODDS in HER-2(+) Breast Cancer

Anatol J Gen Med Res 2021;31(2):253-260
Fatma Özkan 1
Ilkay Tugba Unek 2
Olçun Ümit Ünal 3
Mustafa Emiroğlu 4
Asım Leblebici 5
Hülya Ellidokuz 6
Naciye Ümit Bayol 7
Gönül Demir 8
Harun Akar 9
1. Ayvacık State Hospital, Department of Internal Medicine, Canakkale, Turkey
2. Dokuz Eylul University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Izmir, Turkey
3. University of Health Sciences, Izmir Tepecik Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology, Izmir, Turkey
4. University of Health Sciences, Izmir Tepecik Training and Research Hospital, Department of General Surgery, Izmir, Turkey
5. Dokuz Eylul University, Institute of Health Sciences, Department of Translational Oncology, Izmir, Turkey
6. Dokuz Eylul University, Institute of Oncology, Department of Preventive Oncology, Izmir, Turkey
7. University of Health Sciences, Izmir Tepecik Training and Research Hospital, Department of Pathology, Izmir, Turkey
8. University of Health Sciences, Izmir Tepecik Training and Research Hospital, Department of Radiation Oncology, Izmir, Turkey
9. University of Health Sciences, Izmir Tepecik Training and Research Hospital, Department of Internal Medicine, Izmir, Turkey
No information available.
No information available
Received Date: 2020-03-08T18:45:19
Accepted Date: 2021-08-18T15:44:59
PDF
Cite
Share
Request

Abstract

Objective: The overexpression of human epidermal growht factor-2 (HER-2) receptor is detected in 20% of patients with breast cancer. The prognosis is poor in patients with HER-2(+) breast cancer not receiving systemic therapy. Modified lymph node ratio (mLNR) and log odds of positive lymph nodes (LODDS) are the novel ratio-based classifications of lymph nodes in breast cancer. In literatüre, the data about the prognostic significance of mLNR ve LODDS is limited in patients with HER-2(+) breast cancer. The objective of the study was to evaluate the prognostic significance of mLNR and LODDS in patients with HER-2(+) breast cancer.

Method: This study included 75 patients who were treated with adjuvant chemotherapy and trastuzumab for the diagnosis of HER-2(+) breast cancer between 2008-2013. The patients who received neoadjuvant chemotherapy or patients without axillary dissection were excluded from the study.

Results: The mean disease-free survival and overall survival were 126.36±4.38 months (range: 117.78-134.95) and 128.87±3.32 months (range: 122.37-135.38), respectively. The mean disease-free survival was 127.30 months in patients with mLNR≤ 0.5 and 118.08 months in patients with mLNR> 0.5 (p=0.690). When the patients were classified into three groups according to LODDS values as LODDS1 (LODDS≤ -1.0), LODDS2 (-1.0<LODDS≤0) and LODDS3 (LODDS>0), the mean disease-free survival were 128.65 months, 114.07 months and 111.78 months, respectively (p=0.641).

Conclusion: In this study, patients with HER-2(+) breast cancer were divided into risk groups according to mLNR and LODDS values, and a survival difference that could be clinically meaningful was observed between the groups, but was not statistically significant. There is a need for studies involving more patients on this subject. Our study highlights the prognostic significance of mLNR and LODDS in HER-2(+) breast cancer. Dividing HER-2(+) breast cancer into risk groups through mLNR and LODDS will help clinicians to develop optimal treatment and follow-up strategies.

Keywords:
HER-2 receptor, breast cancer, modified lymph node ratio, LODDS, prognosis
2024 ©️ Galenos Publishing House